↓ Skip to main content

Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial

Overview of attention for article published in Trials, January 2013
Altmetric Badge

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial
Published in
Trials, January 2013
DOI 10.1186/1745-6215-14-53
Pubmed ID
Authors

Anne B Chang, Keith Grimwood, Andrew C Wilson, Peter P van Asperen, Catherine A Byrnes, Kerry-Ann F O’Grady, Theo P Sloots, Colin F Robertson, Paul J Torzillo, Gabrielle B McCallum, Ian B Masters, Helen M Buntain, Ian M Mackay, Jacobus Ungerer, Joanne Tuppin, Peter S Morris

Abstract

Bronchiectasis unrelated to cystic fibrosis (CF) is being increasingly recognized in children and adults globally, both in resource-poor and in affluent countries. However, high-quality evidence to inform management is scarce. Oral amoxycillin-clavulanate is often the first antibiotic chosen for non-severe respiratory exacerbations, because of the antibiotic-susceptibility patterns detected in the respiratory pathogens commonly associated with bronchiectasis. Azithromycin has a prolonged half-life, and with its unique anti-bacterial, immunomodulatory, and anti-inflammatory properties, presents an attractive alternative. Our proposed study will test the hypothesis that oral azithromycin is non-inferior (within a 20% margin) to amoxycillin-clavulanate at achieving resolution of non-severe respiratory exacerbations by day 21 of treatment in children with non-CF bronchiectasis.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Australia 1 2%
Unknown 61 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 19%
Student > Master 10 16%
Student > Doctoral Student 6 10%
Researcher 5 8%
Student > Bachelor 5 8%
Other 18 29%
Unknown 6 10%
Readers by discipline Count As %
Medicine and Dentistry 27 44%
Agricultural and Biological Sciences 6 10%
Nursing and Health Professions 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Psychology 3 5%
Other 10 16%
Unknown 8 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2016.
All research outputs
#14,083,613
of 21,005,902 outputs
Outputs from Trials
#3,683
of 5,368 outputs
Outputs of similar age
#104,321
of 168,986 outputs
Outputs of similar age from Trials
#1
of 1 outputs
Altmetric has tracked 21,005,902 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,368 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,986 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them